us fda clears lp-184: lantern pharma's game-changing ai cancer therapy targets solid tumors
Published 1 year ago • 21 plays • Length 2:01Download video MP4
Download video MP3
Similar videos
-
![[ltrn webinar] - lp-184 in pancreatic cancer and other solid tumors with dr. igor from fccc](https://i.ytimg.com/vi/Kk5-l_vhIuI/mqdefault.jpg)
10:00
[ltrn webinar] - lp-184 in pancreatic cancer and other solid tumors with dr. igor from fccc
-
0:31
lantern pharma (nasdaq: ltrn) is revolutionizing cancer therapy development with its ai platform
-
6:10
lantern pharma's ai-based drug discovery and development targeting cancer
-
37:36
lantern pharma (ltrn) "how ai has lit a revolution in healthcare, medicine, & human longevity"
-
0:17
lantern pharma: redefining oncology drug development with a.i. and machine learning
-
![drug facts - lantern pharma collaboration [may 2023]](https://i.ytimg.com/vi/bxIjkk-q7NY/mqdefault.jpg)
0:26
drug facts - lantern pharma collaboration [may 2023]
-
7:19
how ai is accelerating advancements in oncology | nasdaq breakthrough economy | lantern pharma
-
0:31
artificial intelligence and machine learning in precision medicine - lantern pharma
-
0:55
what is lantern pharma's radr™ system, and how does it help with cancer drug development?
-
0:18
lantern pharma: redefining oncology drug development with a.i. and machine learning
-
49:16
creating an ai-driven biotech for cancer drug development | panna sharma | nasdaq: ltrn
-
6:01
radnet's new fda cleared artificial intelligence technology
-
1:55
lantern pharma: using ai to transform drug development
-
45:39
lantern (ltrn) "how artificial intelligence is crushing drug discovery times & costs in cancer"
-
1:00
this ai-designed drug candidate promises to improve cancer treatment
-
0:46
fda approves capmatinib for advanced lung cancer
-
2:27
hossein ameri, md, phd: pan retinal photocoagulation versus anti-vegf